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Abstract
The generation of disease-specific induced pluri-
potent stem cell (iPSC) lines from patients with in-
curable diseases is a promising approach for studying 
disease mechanisms and drug screening. Such in-
novation enables to obtain autologous cell sources in 
regenerative medicine. Herein, we report the gen-
eration and characterization of iPSCs from fibroblasts 
of patients with sporadic or familial diseases, includ-
ing Parkinson’s disease (PD), Alzheimer’s disease 
(AD), juvenile-onset, type I diabetes mellitus (JDM), 
and Duchenne type muscular dystrophy (DMD), as well 
as from normal human fibroblasts (WT). As an example 
to modeling disease using disease-specific iPSCs, we 
also discuss the previously established childhood cer-
ebral adrenoleukodystrophy (CCALD)- and adreno-
myeloneuropathy (AMN)-iPSCs by our group. Through 
DNA fingerprinting analysis, the origins of generated 
disease-specific iPSC lines were identified. Each iPSC 
line exhibited an intense alkaline phosphatase activity, 
expression of pluripotent markers, and the potential to 
differentiate into all three embryonic germ layers: the 
ectoderm, endoderm, and mesoderm. Expression of 
endogenous pluripotent markers and downregulation 
of retrovirus-delivered transgenes [OCT4 (POU5F1), 
SOX2, KLF4, and c-MYC] were observed in the gen-
erated iPSCs. Collectively, our results demonstrated 
that disease-specific iPSC lines characteristically re-
sembled hESC lines. Furthermore, we were able to dif-
ferentiate PD-iPSCs, one of the disease-specific-iPSC 
lines we generated, into dopaminergic (DA) neurons, 
the cell type mostly affected by PD. These PD-specific 
DA neurons along with other examples of cell models 
derived from disease-specific iPSCs would provide a 
powerful platform for examining the pathophysiology 
of relevant diseases at the cellular and molecular levels 
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Disease 
abbreviation Disease Defect
Used cell
type Age Sex 
PD 
AD 
JDM 
DMD 
CCALD 
AMN 
WT 
Parkinson’s disease
Alzheimer’s disease
Juvenile‐onset,
  type I diabetes mellitus 
Duchenne type
  muscular dystrophy
Adrenoleukodystrophy 
  CCALD type, a subtype of X‐ALD
Adrenoleukodystrophy 
  AMN type, a subtype of X‐ALD 
Human dermal fibroblasts, 
  Isolated from neonatal foreskin
Multifactorial 
25% at risk
  for Alzheimer’s disease
IDDM1 gene defect 
Multifactorial 
ABCD1 gene defect 
ABCD1 gene defect 
N/A 
Fibroblast 
Fibroblast 
Fibroblast 
Fibroblast 
Fibroblast 
Fibroblast 
Fibroblast 
53 yr
18 yr 
20 yr 
15 yr 
  6 yr 
32 yr 
Neonatal 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Generation of CCALD- and AMN-iPSCs was previously reported (Jang et al., 2011), and these cell lines are being stored with other cell lines and open to 
researchers as shown in Table 3. 
Table 1. Fibroblasts of patients with sporadic or familial diseases were used to generate iPSC lines
and for developing new drugs and therapeutic 
regimens.
Keywords: drug evaluation, preclinical; drug screen-
ing; induced pluripotent stem cells; models, biological; 
tissue therapy 
Introduction
Human embryonic stem cells (hESCs) are isolated 
from the inner cell mass of the developing 
blastocyst, indefinitely maintaining their capability 
for self-renewal and pluripotent nature (Thomson 
et al., 1998). By taking advantage of hESC 
characteristics, studies on early human development, 
drug development, and cell-based therapies for 
incurable diseases have become possible (Hattori 
and Fukuda, 2010). However, ethical issues have 
arisen, since hESCs are derived from pre-implantation 
human embryos (Robertson, 2001). Moreover, 
challenging obstacles associated with immune 
rejection after transplantation for cell-replacement 
therapy remained unresolved.
     As a breakthrough discovery in regenerative 
medicine, adult human fibroblasts have been 
successfully reprogrammed via overexpression of 
pluripotency-related transcription factors, which 
include OCT4 (POU5F1), SOX2, KLF4, and 
c-MYC, to establish human induced pluripotent 
stem cells (hiPSCs) (Takahashi et al., 2007). Many 
studies have demonstrated close similarities between 
hiPSCs and hESCs at the molecular and genetic 
level, and in terms of their morphologies and 
functions (Lowry et al., 2008; Chin et al., 2010; 
Hawkins et al., 2010). Disease-specific iPSC lines 
also are accessible since they can be generated 
from patients with sporadic or genetically inherited 
diseases (Dimos et al., 2008; Park et al., 2008; 
Maehr et al., 2009; Soldner et al., 2009; Chamberlain 
et al., 2010; Urbach et al., 2010). The hESC-like 
characteristics allow them to be differentiated into 
various cell types in response to developmental 
cues. Recent reports have described that cell types 
related to the respective disorder are differentiated 
from disease-specific iPSCs and have been able to 
faithfully recapitulate disease phenotypes (Ebert et 
al., 2009; Ku et al., 2010; Itzhaki et al., 2011; Liu et 
al., 2011; Zhang et al., 2011). This landmark 
discovery of hiPSCs has opened a new window for 
developing human disease models in vitro in order 
to investigate pathophysiology and drug development 
(Marchetto et al., 2010; Rashid et al., 2010; Jang 
et al., 2011; Nguyen et al., 2011; Yazawa et al., 
2011). Although the recent studies have shown 
substantial differences between hiPSCs and 
hESCs at the transcriptional, epigenetic, genetic 
and functional levels (Hanna et al., 2009; Ohi et al., 
2011), the value of hiPSCs has been proven as a 
useful tool for in vitro disease modeling. 
     Herein, we report the generation and character-
ization of hiPSCs from fibroblasts of patients who 
have been previously diagnosed with sporadic or 
familial diseases including Parkinson’s disease 
(PD), Alzheimer’s disease (AD), juvenile-onset, 
type I diabetes mellitus (JDM), and Duchenne type 
muscular dystrophy (DMD), as well as from normal 
human fibroblasts (WT). The disease-specific 
hiPSCs can be differentiated into cell-types of their 
relevant diseases. Therefore, these disease-specific 
hiPSCs hold great potential for research and clin-
ical purposes by providing a useful platform for dis-
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Figure 1. Both disease-specific and 
wild-type iPSC lines expressing plu-
ripotent markers similar to hESCs. 
PD-iPSC4, PD-iPSC10, AD-iPSC6, 
AD-iPSC7-5, JDM-iPSC1, DMD- 
iPSC4, DMD-iPSC5, WT-iPSC1, 
and WT-iPSC3 were derived from 
patient-derived fibroblasts as well as 
normal neonatal human dermal fi-
broblasts as shown in Table 1. The 
derivation of CCALD- and AMN- 
iPSC lines has been previously re-
ported (Jang et al., 2011). All estab-
lished iPSC colonies exhibited 
hESC-like morphology. Moreover, 
the established iPSC lines showed 
alkaline phosphatase (AP) activity 
and expressed pluripotency markers. 
4 ,6 -D iam id ino-2-pheny l indo le 
(DAPI) staining was used to de-
termine the total cell content in the 
image. Scale bars = 200 μm.
ease modeling and drug screening. As recently re-
ported, we have established childhood cerebral 
adrenoleukodystrophy (CCALD)- and adrenomye-
loneuropathy (AMN)-iPSCs, and, as a proof-of- 
principle, modeled its diseases (Jang et al., 2011). 
In this study, we generated PD-specific DA neu-
rons from the hiPSCs derived from fibroblasts of 
PD patients. The possibility of applying the 
PD-specific cell models to research and clinical 
purposes is currently under investigation.
Results and Discussion
Establishment and characterization of 
disease-specific hiPSC lines
Patient-derived disease-specific fibroblasts and 
normal neonatal human dermal fibroblasts were re-
programmed by retroviral-mediated delivery of four 
defined factors (OCT4, SOX2, KLF4, and c-MYC) 
(Table 1). After transduction, the fibroblasts were 
cultured for about 4-5 weeks on a feeder layer until 
hESC-like colonies appeared. The colonies were 
picked mechanically and cultured on feeder cells 
for expansion. Since the early-passage hiPSCs 
showed a tendency of losing their stemness or 
spontaneous differentiation, we selected colonies 
that were passage 10 or more to establish stable 
hiPSC lines. These bona fide iPSC lines might be 
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Figure 2. Pluripotency-associated genes in disease-specific cell lines 
show expressions similar to the levels of hESCs. Quantitative real-time 
PCR showed the total expression levels of reprogramming factors, 
OCT4, SOX2, KLF4, and c-MYC as well as the pluripotency-related fac-
tors NANOG and hTERT in hESCs (H9), the indicated parent fibroblasts 
(hFib), and iPSC lines. Distinct expressions similar to those of hESCs, 
but different from those of the parent fibroblasts were observed in most of 
the genes. However, expression levels of KLF4 were high even in most 
of the fibroblasts when compared to those of hESCs. H9 is a human ES 
cell line used as a positive control. PCR reactions were normalized 
against internal controls (β-actin) and plotted relative to expression levels 
in the hESC control. HDFn, normal neonatal human dermal fibroblasts.
derived from either the fully reprogrammed cells or 
epigenetic adjustment of the early-passage re-
programmed cells during continued serial pas-
sages (Mikkelsen et al., 2008; Polo et al., 2010). 
Consistently, the previous report showed that ex-
tended passaging enabled the global gene ex-
pression pattern of hiPSCs similar to that of hESCs 
(Chin et al., 2009; Ohi et al., 2011). 
     To confirm the presence of hESC-like character-
istics, the expanded iPSC colonies were charac-
terized at the molecular and genetic level; the colo-
nies showed significant expression of multiple un-
differentiation markers such as alkaline phospha-
tase (AP), OCT4, SOX2, NANOG, SSEA4, 
TRA-1-81, and TRA-1-60 (Figure 1). In addition, 
quantitative real-time PCR (qRT-PCR) analysis al-
so demonstrated comparable level of expression of 
the well-known undifferentiation marker genes in-
cluding OCT4, SOX2, KLF4, c-MYC, NANOG, and 
hTERT, as in H9-hESCs (Figure 2). In harmony 
with the previous observations, the exogenously in-
troduced transgenes were silenced in iPSC lines 
while high expressions of pluripotency genes 
(OCT4, SOX2, KLF4, and c-MYC) were found from 
endogenous loci (Figure 3). Bisulfite genomic se-
quencing analyses showed that OCT4 promoter re-
gions were hypomethylated in disease-specific 
hiPSCs relative to the parental fibroblasts (data not 
shown). DNA fingerprint analysis of short tandem 
repeats (STRs) revealed that each established 
hiPSC line was identical to its parental somatic cell 
line (Table 2). No aneuploidy was observed in all of 
the hiPSC lines (Figure 4). Although each hiPSC 
line is morphologically indistinguishable and meets 
the gold standard requirements for hiPSCs, the 
colonies vary in the extent of pluripotent marker ex-
pression and transgene silencing of hiPSCs, which 
was potentially caused by differential viral in-
tegration, culture conditions, passage number, and 
batch effects (Ohi et al., 2011). In addition, differ-
ences in origin, the epigenetic signatures and the 
genetic background of the patients’ somatic cells 
used for reprogramming might also influence the 
variability in reprogramming status of the hiPSCs 
obtained (Mikkelsen et al., 2008; Kim et al., 
2010a). For example, Raya et al. showed that so-
matic cells from patients with Franconi’s anemia 
(FA) were refractory to reprogramming, making it 
difficult to model such condition in vitro, due to the 
genetic instability and apoptotic predisposition of 
FA cells. They successfully generated hiPSCs from 
patients with FA only after correction of FA-related 
gene (Raya et al., 2009).
     Human pluripotent stem cells including hiPSCs 
have the ability to differentiate into all three 
embryonic germ layers: ectoderm, endoderm, and 
mesoderm. It was reported that early-passage 
iPSC lines have the tendency of differentiate 
preferentially into the cell lineage of origin and 
continuous passaging abrogates these preferences 
in the differentiation potentials to established 
iPSCs (Chin et al., 2009; Polo et al., 2010). Using 
the previously described method (Kim et al., 
2010b), embryoid bodies (EBs) were formed from 
the iPSC lines at over 10 passages in order to 
avoid preferential differentiation potentials, and 
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Figure 3. Analysis for the reactivation of endogenous pluripotency-related genes such as OCT4, SOX2, KLF4, and c-MYC in iPSC lines. The semi-quanti-
tative RT-PCR analysis showed the relative expression levels of four pluripotency-promoting genes: OCT4, SOX2, KLF4, and c-MYC in PD-, AD-, JDM-, 
DMD-, WT-iPSCs, and their fibroblasts. Specific primers were used to determine the expression levels of endogenous (Endo), virally-delivered transgenes 
(Trans) and the total expression (Total) for each cell line. All the disease-specific iPSC lines showed reactivation of endogenous reprogramming tran-
scription factors while the expressions of retrovirus-delivered transgenes were reduced to low or undetectable levels in the iPSC lines. hESCs and fibro-
blasts were used as positive and negative controls. GAPDH shown at the bottom was used as a loading control for each lane. 
Figure 4. Disease-specific and 
wild-type iPSC lines have normal 
karyotypes. When chromosomal 
contents were analyzed with high 
resolution G-banding karyotypes, the
cell lines, which included PD-iPSC4, 
PD-iPSC10, AD-iPSC6, AD-iPSC7-5, 
JDM-iPSC1, DMD-iPSC4, DMD- 
iPSC5, WT-iPSC1, and WT-iPSC3 
at over 20 passages, indicated nor-
mal diploid chromosomal contents. 
then allowed to spontaneously differentiate into 
three germ layers. Ectodermal lineages were 
confirmed by expressions of Nestin and Pax6, 
while endodermal lineages were determined through 
expressions of HNF3β  and AFP. Expressions of 
brachyury, on the other hand, confirmed mesodermal 
lineages of spontaneously differentiated iPSC lines 
(Figure 5). 
     Taken together, these data indicate that primary 
fibroblasts from patients with sporadic or familial 
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Figure 5. EB-based differentiation 
of iPSC lines reveals three line-
age-specific marker expressions. 
Disease-specific and wild-type iPSC 
lines were spontaneously differ-
entiated in hESC medium without 
bFGF for the formation of EBs. Two 
weeks later, EBs were attached on a 
gelatin coated dish and allowed to 
differentiate into all three germ lay-
ers for 10 days. Immunostaining was 
performed using antibodies specific 
to ectoderm (Nestin, green; Pax6, 
red), endoderm [AFP (α-fetopro-
tein), green; HNF3β, red], and mes-
oderm (Brachyury, green) lineages. 
Scale bars = 100 μm.
diseases were successfully reprogrammed into 
hiPSCs. 
Differentiation of disease-specific hiPSCs into 
disease-relevant cells: disease modeling and 
platforms for new drug discovery
One of the most important aspects of hiPSC 
technology is modeling human diseases using 
patient-derived hiPSCs. Recapitulation of phenotypes 
of relevant diseases using disease-specific hiPSCs 
would provide a unique opportunity to study 
etiopathophysiology of the diseases and to 
develop new therapeutic regimens or drugs. To 
generate cell models of diseases, differentiation of 
disease-specific iPSCs into cell types relevant to 
the diseases is absolutely required. 
     In an effort to establish cell models of PD, we 
sought to differentiate PD-iPSCs into DA neurons 
which are mostly affected in PD by introducing 
morphogens and neurotrophins (Cho et al., 2008). 
As previously reported (Kim et al., 2010b), BMP 
and Activin/Nodal signals were simultaneously 
inhibited by introduction of small molecules such 
as dorsomorphin (DM) and SB431542 (SB) during 
EB formation to obtain neural rosette structures. 
Using sonic hedgehog homolog (SHH) and fibroblast 
growth factor 8 (FGF 8), we regionalized 
PD-iPSC-derived neural rosette cells, and terminally 
differentiated them into DA neurons with GDNF, 
BDNF, TGF-β3, cAMP and ascorbic acid. After the 
terminal differentiation, Tuj1 (beta-tubulin class III; 
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Figure 6. Differentiation of PD-iPSCs 
into DA neurons. The identity of DA 
neurons was confirmed via TH pos-
itive neurons co-expressing Tuj1, 
Nurr1, Pitx3, AADC. The total cell 
content in the merged image was 
represented via DAPI (blue) staining. 
Scale bar = 100 μm. 
a microtubule element expressed exclusively in 
neurons), TH (tyrosine hydroxylase; a rate-limiting 
enzyme in the production of dopamine), Nurr1 
(nuclear receptor related 1 protein; a key nuclear 
receptor protein implicated in the DA differentiation 
of the embryonic brain), Pitx3 (paired-like 
homeodomain 3, a essential transcription factor in 
the development and survival of A9 midbrain DA 
neurons), and AADC (aromatic-L-amino-acid 
decarboxylase; a key enzyme in the formation of 
biogenic trace amines such as DA and serotonin)- 
expressing cells were detected by immunostaining 
using antibodies against Tuj1, TH, Nurr1, Pitx3, 
and AADC (Figure 6). Our result indicated that the 
PD-iPSCs we generated retained potential to 
differentiate into DA neurons in vitro. The 
possibility of using the PD-DA neurons as a cell 
model for research and clinical purposes is under 
investigation. 
     Many studies have recently demonstrated 
patient-specific iPSCs as an important source for 
cell models to study etiopathophysiology of several 
diseases. For example, a progressive degeneration 
of motor neurons was observed during differentiation 
from spinal muscular atrophy (SMA)-iPSCs (Ebert et 
al., 2009). Cardiomyocytes derived from LEOPARD 
syndrome iPSCs were found to reflect the hypertrophic 
features related to this disease (Carvajal-Vergara 
et al., 2010). Similarly, cardiomyocytes produced 
from Long QT and Timothy syndrome patient 
iPSCs had the prolonged duration of action 
potentials, as is seen in these patients (Moretti et 
al., 2010; Yazawa et al., 2011). RETT syndrome 
patient iPSCs reproduced the decreased number of 
glutamatergic synapses and calcium transients, as 
might be relevant to the clinical features of RETT 
(Marchetto et al., 2010). Familial dysautonomia 
iPSC-derived neural crest precursor cells exhibited 
reduced neurogenic differentiation and migration 
associated with these disease phenotypes (Lee et 
al., 2009). Smooth muscle cells differentiated from 
Hutchinson-Gilford progeria patient iPSCs gave 
rise to premature senescence, vascular aging 
defects seen in patients (Liu et al., 2011; Zhang et 
al., 2011). Importantly, the defects of neurons 
derived from SMA-, familial-dysautonomia-, and 
RETT-iPSCs were partially ameliorated by the 
treatment with small-molecule candidates or 
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Disease Cell‐lines DNA fingerprinting
Pluripotency marker 
Mycoplasma 
test
Formation 
of 
3 germ layer 
Karyotyping OCT4
SSEA4 
SOX2
TRA‐1‐81 
NANOG 
TRA‐1‐60 
AP
activity 
PD
AD
JDM 
DMD
CCALD
AMN
HDFn
PD‐iPSC4 
PD‐iPSC10 
AD‐iPSC4 
AD‐iPSC6 
AD‐iPSC7‐5 
JDM‐iPSC1 
DMD‐iPSC4 
DMD‐iPSC5 
CCALD‐iPSC2 
CCALD‐iPSC6 
CCALD‐iPSC10 
CCALD‐iPSC14 
AMN‐iPSC1 
AMN‐iPSC3 
AMN‐iPSC4 
WT‐iPSC1 
WT‐iPSC3 
○ 
○
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
○ 
○
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
○ 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
46, XY 
17 cell lines are being distributed for research purposes. 
Table 3. List of iPSC lines in Korea Stem Cell Bank (http://koreastemcellbank.org/)
previously reported candidate drugs, further 
supporting the idea that disease specific-iPSCs 
would provide cell models for research and clinical 
purposes (Ebert et al., 2009; Lee et al., 2009; 
Marchetto et al., 2010). 
     Our group has recently established iPSCs from 
fibroblasts of patients with CCALD and AMN and 
used the cells to generate cell models to study 
X-linked Adrenoleukodystrophy (X-ALD) (Jang et 
al., 2011). Oligodendrocytes differentiated from 
CCALD-iPSCs displayed a significant accumulation 
of intracellular very long chain fatty acids (VLCFAs), 
recapitulating pathophenotypical characteristics 
observed in the patients with this disease. 
Furthermore, we also observed a decrease in the 
accumulated VLCFA by chemical treatment to 
induce expression of the closest homolog of the 
ABCD1 transporter, ABCD2. Therefore, the cell 
model derived from CCALD-iPSCs would be 
potentially of great use in screening or testing the 
efficacy of new drugs to treat patients suffering 
from CCALD. 
     Herein, we have shown the establishment of 
iPSCs from patients who were previously diagnosed 
with sporadic or familial diseases and the potential 
of iPSCs to differentiate into disease-relevant cells. 
The generated disease-specific iPSC lines were 
exclusively stored and maintained by the Stem Cell 
Bank in Korea and are available to all researchers 
who study the pathophysiologies of incurable 
diseases and drug discovery (Table 3). Recent 
studies regarding disease models developed from 
patient-derived iPSCs have shown the effectiveness 
of disease-specific iPSCs in terms of potentials in 
specialized cell differentiation, understanding human 
disease mechanisms and new drug screening. 
Although the field of iPSCs has developed rapidly 
in the past several years, the field remains 
relatively young and holds many questions to be 
answered. 
Methods
Culture of fibroblasts
Primary fibroblast of patients with Parkinson’s disease (PD, 
AG20442), Alzheimer’s disease (AD, AG07889), juve-
nile-onset, type I diabetes mellitus (JDM, GM01911), 
Duchene type muscular dystrophy (DMD, GM05128), and 
normal control fibroblasts (HDFn, SKU#C-004-5C) were 
purchased from Coriell and Invitrogen. Purchased primary 
fibroblasts were cultured under culture conditions recom-
mended by the manufacturers.
Retroviral transduction and maintenance of iPSCs
A pMSCV vector containing a c-MYC human sequence 
and pMIG vectors containing OCT4, SOX2, and KLF4 hu-
man sequences were obtained from Addgene. 293GPG 
cells were transfected using retroviral vectors. A day after 
transfection, viral supernatants were collected for a 9 
day-long period. Obtained supernatants were concentrated 
by ultracentrifugation. Primary skin fibroblasts were trans-
duced for a day and on the 5th day post infection, infected 
cells were re-plated onto STO feeder cells. Re-plated cells 
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were cultured in hESC medium including basic fibroblast 
growth factor (bFGF; 10 ng/ml) for 3-4 weeks. Apparent 
colonies on STO feeder cells were mechanically picked 
and transferred once every week. After 10 passages, the 
concentration of bFGF was changed to 4 ng/ml.
Alkaline phosphatase staining and 
immunocytochemistry 
Alkaline phosphatase staining was performed following the 
manufacturer’s recommended procedure (Sigma-Aldrich). 
Cells were fixed in 4% paraformaldehyde for 30 min, per-
meabilized with 0.1% Triton X-100 for 10 min, and blocked 
in 2% BSA in PBS for 1 h. Cells were then incubated with 
the appropriate primary antibodies against NANOG (R&D 
systems), OCT4 (Santa Cruz), SOX2 (Chemicon), SSEA4 
(Chemicon), TRA-1-81 (Chemicon), TRA-1-60 (Chemicon), 
HNF3β (Santa Cruz), Brachyury (Santa Cruz), PAX6 (DSHB), 
Tuj1 (COVANCE), Nestin (Chemicon), TH (Pelfreez), Nurr1 
(Millipore), Pitx3 (Millipore), and AADC (Millipore). 
Appropriate Alexa Fluor 488- or 568-labeled secondary an-
tibodies (Molecular Probes) were treated for 1 h.
Gene expression analysis
Total RNA preparation was conducted for iPSCs, control 
hESCs, and fibroblasts using the Total RNA extraction kit 
(Intron Biotechnology) and converted to complementary 
DNA using the iScriptTM cDNA Synthesis Kit (BIO-RAD). 
Semi-quantitative RT-PCR was performed with EmeraldAmp 
GT PCR Master Mix (Takara Bio Inc.) and quantitative 
RT-PCR was carried out using specific primers (Park et al., 
2008). Quantitative RT-PCR was performed with SYBR 
premix Ex taq (Takara Bio Inc.) in the C1000TM thermal cy-
cler (BIO-RAD).
DNA fingerprinting analysis
PCR based DNA fingerprint analysis of iPSCs were per-
formed by Humanpass Inc. (Seoul, Korea) using a stand-
ard protocol for short tandem repeats (STR).
Karyotype analysis
Chromosomal studies were performed at GenDix, Inc. 
(Seoul, Korea) using standard protocols for GTG banding.
Differentiation of iPSCs into three-germ layer cell 
types
Disease-specific iPSCs were washed with PBS and 2 
mg/ml collagenase was introduced for an hour. Detached 
colonies were collected, washed with EB medium (80% 
DMEM/F12, 20% KO serum replacement, 1 mM L-glutamine, 
0.1 mM nonessential amino acids, 0.1 mM 2-mercaptoethanol, 
100 U/ml penicillin and 100 μg/ml streptomycin) and gently 
resuspended in EB medium with 5% FBS. EBs were 
formed by culturing colonies in suspension and the me-
dium was changed every other day. Suspension culture 
was continued for a week and EBs were then attached on-
to Matrigel (BD) coated culture dishes. They were main-
tained for an additional 7 days for differentiation and the 
medium was changed every other day.
Differentiation of iPSCs into DA neurons 
Differentiation of DA neurons was performed according to 
our established protocols with a slight modification (Cho et 
al., 2008; Kim et al., 2010b). First, iPSCs were washed 
with PBS and 2 mg/ml collagenase was introduced for an 
hour. Following our previously established protocol, EBs 
were cultured for 4 days in the presence of DM and SB 
(Kim et al., 2010b).
     For differentiation to DA neurons, EBs were attached 
onto Matrigel-coated culture dishes and cultured for 5 days 
to generate neural rosette structures expressing neural 
stem cell markers such as Nestin and Pax6. Neural ro-
settes were isolated mechanically to obtain a high pop-
ulation of neural precursor cells (NPCs), and they were cul-
tured on Matrigel-coated culture dishes for expansion. In 
order to induce DA neurons, NPCs were cultured in me-
dium with SHH and FGF8 for 8 days and terminally differ-
entiated in the presence of GDNF, BDNF, TGF-β3, cAMP 
and ascorbic acid in the culture medium for about 2 weeks.
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